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background: As ticagrelor enters into clinical use for acute coronary syndrome, it is important to understand patient/physician behavior in terms 
of appropriate use, adherence, and event rates.
methods: Saskatchewan Registry is a prospective, observational, multi-center cohort study within the Regina Qu’Appelle Health Region (one PCI 
and nine non-PCI facilities). Consecutive patients started on ticagrelor at the PCI facility were indentified, and consented. PLATO inclusion/exclusion 
criteria were used to assess appropriateness use.
results:Starting April of 2012, to September of 2013, 227 patients were initiated on ticagrelor, with mean age of 62.2 12.1, 66% male, and mean 
follow up of 157.4 111.7 days. Seventy-four of the 227 (32.4%) patients who took ticagrelor had an off-label PLATO indications. Forty-seven patients 
(20.7%) prematurely stopped taking ticagrelor and, were more likely to be older, female, non-white, present with shock, and complain of dyspnea. 
The composite event rate (death from a vascular cause, myocardial infarction, or stroke) was 8.8% with predictors of events depicted in figure below
Conclusions: In this first exclusive description of ticagrelor adoption use in a real-world setting, up to 1/3rd of indications for use of ticagrelor 
are considered off-label, about 1/5th of patients started on ticagrelor prematurely stopped the medication. Premature discontinuation was an 
independent predictor of death from vascular causes, myocardial infarction or stroke.
 
